BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Varona JF, Landete P, Lopez-Martin JA, Estrada V, Paredes R, Guisado-Vasco P, Fernandez de Orueta L, Torralba M, Fortun J, Vates R, Barberan J, Clotet B, Ancochea J, Carnevali D, Cabello N, Porras L, Gijon P, Monereo A, Abad D, Zuñiga S, Sola I, Rodon J, Vergara-Alert J, Izquierdo-Useros N, Fudio S, Pontes MJ, de Rivas B, Giron de Velasco P, Nieto A, Gomez J, Aviles P, Lubomirov R, Belgrano A, Sopesen B, White KM, Rosales R, Yildiz S, Reuschl AK, Thorne LG, Jolly C, Towers GJ, Zuliani-Alvarez L, Bouhaddou M, Obernier K, McGovern BL, Rodriguez ML, Enjuanes L, Fernandez-Sousa JM, Krogan NJ, Jimeno JM, Garcia-Sastre A. Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19. Life Sci Alliance 2022;5:e202101200. [PMID: 35012962 DOI: 10.26508/lsa.202101200] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Mohamed Y, El-maradny YA, Saleh AK, Nayl AA, El-gendi H, El-fakharany EM. A comprehensive insight into current control of COVID-19: Immunogenicity, vaccination, and treatment. Biomedicine & Pharmacotherapy 2022;153:113499. [DOI: 10.1016/j.biopha.2022.113499] [Reference Citation Analysis]
2 He W, Gao Y, Zhou J, Shi Y, Xia D, Shen HM. Friend or Foe? Implication of the autophagy-lysosome pathway in SARS-CoV-2 infection and COVID-19. Int J Biol Sci 2022;18:4690-703. [PMID: 35874956 DOI: 10.7150/ijbs.72544] [Reference Citation Analysis]
3 Sukmarini L. Antiviral Peptides (AVPs) of Marine Origin as Propitious Therapeutic Drug Candidates for the Treatment of Human Viruses. Molecules 2022;27:2619. [PMID: 35565968 DOI: 10.3390/molecules27092619] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Chourasia R, Padhi S, Phukon LC, Abedin MM, Sirohi R, Singh SP, Rai AK. Peptide candidates for the development of therapeutics and vaccines against β-coronavirus infection. Bioengineered 2022;13:9435-54. [PMID: 35387556 DOI: 10.1080/21655979.2022.2060453] [Reference Citation Analysis]
5 Howell R, Clarke MA, Reuschl A, Chen T, Abbott-imboden S, Singer M, Lowe DM, Bennett CL, Chain B, Jolly C, Fisher J. Executable network of SARS-CoV-2-host interaction predicts drug combination treatments. npj Digit Med 2022;5. [DOI: 10.1038/s41746-022-00561-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Sachse M, Tenorio R, Fernández de Castro I, Muñoz-basagoiti J, Perez-zsolt D, Raïch-regué D, Rodon J, Losada A, Avilés P, Cuevas C, Paredes R, Segalés J, Clotet B, Vergara-alert J, Izquierdo-useros N, Risco C. Unraveling the antiviral activity of plitidepsin by subcellular and morphological analysis. Antiviral Research 2022. [DOI: 10.1016/j.antiviral.2022.105270] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]